Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program (Q37489472)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 May 2009

Language	Label	Description	Also known as
English	Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program	scientific article published on 19 May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

0 references

arterial hypertension

0 references

liver cirrhosis

0 references

0 references

portal hypertension

1 reference

based on heuristic

inferred from title

author name string

Guadalupe Garcia-Tsao

1

1 reference

Europe PubMed Central

20 August 2017

Joseph K Lim

2

1 reference

Europe PubMed Central

20 August 2017

Members of Veterans Affairs Hepatitis C Resource Center Program

3

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

19 May 2009

1 reference

Europe PubMed Central

20 August 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

20 August 2017

104

1 reference

Europe PubMed Central

20 August 2017

1802-1829

1 reference

Europe PubMed Central

20 August 2017

7

1 reference

Europe PubMed Central

20 August 2017

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pharmacological treatment of portal hypertension: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic band ligation in the treatment of portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Drug administration in chronic liver disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The use of self-expanding metal stents to treat acute esophageal variceal bleeding.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic treatments for portal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Portal hypertension and gastrointestinal bleeding.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Spontaneous bacterial peritonitis: a historical perspective

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention and treatment of infections in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Restricted use of albumin for spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diuresis in the ascitic patient: a randomized controlled trial of three regimens

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hyponatremia in cirrhosis: Results of a patient population survey.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hyponatremia and mortality among patients on the liver-transplant waiting list

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Peritoneovenous shunt as a bridge to liver transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Outcome analysis of cirrhotic patients undergoing chest tube placement.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Tenofovir disoproxil fumarate: role in hepatitis B treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acute kidney injury in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pathogenesis and treatment of hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Diagnosis and treatment of acute renal failure in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Model for end-stage liver disease (MELD) and allocation of donor livers

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

The treatment of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

ESPEN Guidelines on Enteral Nutrition: Liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Dietary and nutritional indications in hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Fine-needle aspiration biopsy of hepatic lesions: computerized tomographic-guided versus endoscopic ultrasound-guided FNA.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Compensated cirrhosis: Natural history and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.191

21 January 2018

Identifiers

10.1038/AJG.2009.191

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37489472&oldid=1707451753"